Literature DB >> 19562511

Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity.

Argyri Gialeraki1, Christos Markatos, Elisabeth Grouzi, Efrosyni Merkouri, Anthi Travlou, Marianna Politou.   

Abstract

Acenocoumarol is mainly catabolized by CYP2C9 isoform of cytochrome P450 (CYP) liver complex and exerts its anticoagulant effect through the inhibition of Vitamin K Epoxide Reductase (VKOR). The most important genetic polymorphisms which lead to an impaired enzymatic activity and therefore predispose to acenocoumarol sensitivity, are considered to be CYP2C9*2 (Arg144Cys), CYP2C9*3 (Ile359Leu) and VKORC1-1639G>A, respectively. In this study we compared the results of the PGXThrombo StripAssay kit (ViennaLab Diagnostics,Vienna, Austria) with direct DNA sequencing and in house Restriction Fragment Length Polymorphisms (RFLP) for the detection of the aforementioned Single Nucleotide Polymorphisms (SNPs). The reverse hybridization StripAssay was found to be equally effective with RFLP and direct DNA sequencing for the detection of CYP2C9*2 and CYP2C9*3 polymorphisms, respectively. The comparison of the RFLP reference method with the reverse hybridization StripAssay for the detection of VKORC1-1639 G>A polymorphism showed that the reverse hybridization StripAsssay might misclassify some A/A homozygotes as heterozygotes. Optimization of the hybridization procedures may eliminate the extra low signal band observed in some samples at the reverse hybridization StripAssay and improve its diagnostic value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562511     DOI: 10.1007/s11033-009-9587-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  17 in total

1.  Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.

Authors:  José Hermida; José Zarza; Ignacio Alberca; Ramón Montes; María Luz López; Eva Molina; Eduardo Rocha
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

2.  Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations.

Authors:  Umit Yasar; Eleni Aklillu; Roberto Canaparo; Mia Sandberg; Jane Sayi; Hyung-Keun Roh; Agneta Wennerholm
Journal:  Eur J Clin Pharmacol       Date:  2002-11-01       Impact factor: 2.953

Review 3.  The pharmacogenetics of coumarin therapy.

Authors:  Deepak Voora; Howard L McLeod; Charles Eby; Brian F Gage
Journal:  Pharmacogenomics       Date:  2005-07       Impact factor: 2.533

4.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Authors:  Hsiang-Yu Yuan; Jin-Jer Chen; M T Michael Lee; Ju-Chieh Wung; Ying-Fu Chen; Min-Ji Charng; Ming-Jen Lu; Chi-Ren Hung; Chun-Yu Wei; Chien-Hsiun Chen; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

Review 5.  Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Authors:  Tong Yin; Toshiyuki Miyata
Journal:  Thromb Res       Date:  2006-12-11       Impact factor: 3.944

6.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.

Authors:  Alan H B Wu; Ping Wang; Andrew Smith; Christine Haller; Katherine Drake; Mark Linder; Roland Valdes
Journal:  Pharmacogenomics       Date:  2008-02       Impact factor: 2.533

8.  VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.

Authors:  Christos N Markatos; Elissavet Grouzi; Marianna Politou; Argyri Gialeraki; Efrosyni Merkouri; Ioannis Panagou; Ioanna Spiliotopoulou; Anthi Travlou
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

Review 9.  VKORC1: molecular target of coumarins.

Authors:  J Oldenburg; M Watzka; S Rost; C R Müller
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

Review 10.  Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.

Authors:  Johannes Oldenburg; Carville G Bevans; Andreas Fregin; Christof Geisen; Clemens Müller-Reible; Matthias Watzka
Journal:  Thromb Haemost       Date:  2007-09       Impact factor: 5.249

View more
  3 in total

1.  Prevalence of H1299R polymorphism in the Factor V gene among the Taif-Saudi Arabia population using polymerase chain reaction-reverse hybridization technique.

Authors:  Nabil Saied Awad; Adel El-Sayed El-Tarras
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

2.  Association of FV G1691A Polymorphism but not A4070G With Coronary Artery Disease.

Authors:  Ahmed Amara; Meriem Mrad; Aicha Sayeh; Abdeddayem Haggui; Dhaker Lahideb; Najiba Fekih-Mrissa; Habib Haouala; Brahim Nsiri
Journal:  Clin Appl Thromb Hemost       Date:  2017-11-27       Impact factor: 2.389

3.  DNA and RNA analyses in detection of genetic predisposition to cancer.

Authors:  Grzegorz Kurzawski; Dagmara Dymerska; Pablo Serrano-Fernández; Joanna Trubicka; Bartłomiej Masojć; Anna Jakubowska; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2012-12-04       Impact factor: 2.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.